Finance

I-Mab dips in NASDAQ debut, first in years for an innovative Chinese biopharma

Shares of I-Mab slipped 11% in their first day of trading Friday after the Shanghai-based company priced its IPO on NASDAQ within its proposed range, raising $104 million to fund its cross-border development strategy. The...

Define Ventures closes first digital health fund with $87M

Led by a former Kleiner Perkins partner, Define Ventures launched Monday with an $87 million first fund, which will invest in early stage digital health companies. Founder and Managing Partner Lynne Chou O'Keefe was a...

Novo seeks to REPAIR funding in antibiotics companies

In response to an expanding funding gap for antimicrobial resistance companies, Novo Holdings is expanding the remit of its early stage REPAIR Impact Fund to include investments as late as Phase II for the fund’s...

Sofinnova Partners vet Tordjman launches Jeito with €200M first biotech fund

Paris-based Jeito Capital launched Monday with the €200 million ($223.1 million) close of its first fund, which the firm will invest in 15 therapeutics start-ups, primarily in Europe. Jeito founder and CEO Rafaèle Tordjman was...

The AMR crisis is solvable -- but we must act together and fast

Antimicrobial resistance is one of the most serious threats to humanity. This year, a staggering 700,000 people will die from infections that cannot be treated by most or all available antibiotics. Sadly, this number will...

Frazier taking new company creation angle with $617M fund

For its latest and largest venture fund, Frazier Healthcare Ventures aims to conduct more company creation around novel targets while continuing to focus on its core areas of investment. The firm will soon begin investing...

Emendo raises $61M series B for allele-specific gene editing

Gene editing company Emendo raised $61 million in a series B round led by Japanese biopharma AnGes. Emendo plans to partner with AnGes, which is developing gene and oligonucleotide-based therapies, on treatments for undisclosed diseases....

UPMC venture arm to invest $1B in up to 50 life sciences companies

UPMC Enterprises has committed to invest $1 billion in life sciences companies developing new drugs, diagnostics and devices by the end of 2024. EVP Jeanne Cunicelli told BioCentury that the venture and commercialization arm of...

Jan. 14 Financial Quick Takes: Schrödinger proposes NASDAQ IPO; plus Mirati, Blackstone, Orexia, Jasper, seqWell

Schrödinger seeking NASDAQ listing  Computational physics and drug discovery company Schrödinger Inc. proposed to raise up to $100 million in an IPO on NASDAQ. The company’s largest shareholders are the Bill and Melinda Gates Foundation...

Tyra raises $50M series A for cancer drug resistance

Tyra Biosciences emerged from stealth with a $50 million series A round to bring its first therapy to the clinic for drug-resistant cancer. Alta Partners, RA Capital Management, Boxer Capital of Tavistock Group and Canaan...

All chips on immuno-oncology is not a good gamble

While first-generation immuno-oncology therapies are only the tip of the iceberg of what immune reprogramming promises to do for patients, the massive investment in the space has entered bubble territory, with the inflating number of...

Pact’s $75M series C gives Vida’s Kite alumni long-sought stab at personalized cell therapy

By leading Pact Pharma Inc.’s $75 million series C round, the ex-Kite partners at Vida Ventures finally have a chance to advance neoantigen-specific T cells for solid tumors, an area of keen interest they weren’t...

Crossover investors help Generation Bio land $110M series C to expand non-viral gene therapy platform

Since raising its $100 million series B round in 2018, Generation Bio has developed a GMP-ready manufacturing process for its non-viral gene therapies and developed a way to target them to specific tissues. The company...

Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area. Positive regulatory signals are converging...

Jan. 9 Financial Quick Takes: Closes for two royalty funds; plus Apellis leads follow-on trio, Element, Omniome, Hinova, Emergex, Tscan, Calliditas

HealthCare Royalty, Sagard close royalty funds  HealthCare Royalty Partners closed its HealthCare Royalty Partners IV fund at $1.8 billion. The firm also promoted four team members to managing director: Carlos Almodóvar, head of IR; Shin...